Vincendeau S, Jiang S, Varghese D, Corman S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Scailteux LM, Hussain A. Non-metastatic castration-resistant prostate cancer treated with androgen receptor axis targeting agents - French trends. Clin Onco. 2022 Dec 2;6(15):1-9.
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.